PPIs Get AHRQ Stamp Of Approval Vs. Surgery; Generics Could Be Big Winners
Executive Summary
The Agency for Healthcare Research & Quality's study on the effectiveness of proton pump inhibitors could lead to more difficulties for brand companies in seeking formulary placement
You may also be interested in...
Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says
The safety benefit of Pfizer's COX-2 inhibitor Celebrex compared to non-selective nonsteroidal anti-inflammatory drugs is affirmed in a draft report from the Agency for Healthcare Research & Quality on osteoarthritis treatments
AHRQ Comparative Effectiveness Reviews Will Expand Beyond Medicare
The Agency for Healthcare Research & Quality is preparing to expand the scope of its comparative effectiveness reviews beyond the Medicare population
AHRQ Comparative Effectiveness Reviews Will Expand Beyond Medicare
The Agency for Healthcare Research & Quality is preparing to expand the scope of its comparative effectiveness reviews beyond the Medicare population